MX367279B - Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. - Google Patents

Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.

Info

Publication number
MX367279B
MX367279B MX2015003061A MX2015003061A MX367279B MX 367279 B MX367279 B MX 367279B MX 2015003061 A MX2015003061 A MX 2015003061A MX 2015003061 A MX2015003061 A MX 2015003061A MX 367279 B MX367279 B MX 367279B
Authority
MX
Mexico
Prior art keywords
mhc class
cell receptors
mage
restricted
receptors recognizing
Prior art date
Application number
MX2015003061A
Other languages
English (en)
Other versions
MX2015003061A (es
Inventor
F Robbins Paul
A Rosenberg Steven
Yao Xin
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2015003061A publication Critical patent/MX2015003061A/es
Publication of MX367279B publication Critical patent/MX367279B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G01N33/575—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un receptor de la célula T purificada o aislada (TCR) teniendo especificidad antigénica para MHC de MAGE-A3 de Clase II restringida. La invención además proporciona polipéptidos y proteínas relacionados, así como ácidos nucleicos, vectores de expresión recombinante, células huéspedes y poblaciones de células. Además se proporcionan en la invención anticuerpos o una porción de unión al antígeno de los mismos y composiciones farmacéuticas relacionas a los TCRs de la invención. Además se proporcionan en la invención los métodos para la detección de la presencia de cáncer en un huésped y los métodos para tratar o prevenir el cáncer en un mamífero.
MX2015003061A 2012-09-14 2013-09-13 Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. MX367279B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261701056P 2012-09-14 2012-09-14
PCT/US2013/059608 WO2014043441A1 (en) 2012-09-14 2013-09-13 T cell receptors recognizing mhc class ii-restricted mage-a3

Publications (2)

Publication Number Publication Date
MX2015003061A MX2015003061A (es) 2015-11-06
MX367279B true MX367279B (es) 2019-08-13

Family

ID=49253425

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003061A MX367279B (es) 2012-09-14 2013-09-13 Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
MX2019009641A MX2019009641A (es) 2012-09-14 2015-03-10 Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019009641A MX2019009641A (es) 2012-09-14 2015-03-10 Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida.

Country Status (20)

Country Link
US (4) US9879065B2 (es)
EP (3) EP3636665B1 (es)
JP (4) JP6461796B2 (es)
KR (4) KR102370307B1 (es)
CN (2) CN104968675B (es)
AU (4) AU2013315391B2 (es)
CA (1) CA2884743C (es)
CY (1) CY1122720T1 (es)
DK (2) DK3636665T3 (es)
ES (2) ES2925307T3 (es)
HR (1) HRP20200325T1 (es)
HU (1) HUE048014T2 (es)
IL (3) IL286786B (es)
LT (1) LT2895509T (es)
MX (2) MX367279B (es)
PL (1) PL2895509T3 (es)
PT (1) PT2895509T (es)
SI (1) SI2895509T1 (es)
SM (1) SMT202000103T1 (es)
WO (1) WO2014043441A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3636665B1 (en) * 2012-09-14 2022-06-29 The United States of America, as represented by The Secretary, Department of Health and Human Services T cell receptors recognizing mhc class ii-restricted mage-a3
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
JP6686008B2 (ja) * 2014-10-02 2020-04-22 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
CN107075479A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
PH12021550850A1 (en) * 2015-03-27 2022-10-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
EP3416668A4 (en) * 2016-02-18 2020-02-19 The Wistar Institute Of Anatomy And Biology METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
RS63727B1 (sr) 2016-03-16 2022-12-30 Immatics Biotechnologies Gmbh Transficirane t ćelije i t-ćelijski receptori za upotrebu u imunoterapiji protiv malignih tumora
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018097951A1 (en) 2016-11-22 2018-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3/a6 antibodies
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术（广东）有限公司 源自于mage b6的肿瘤抗原短肽
CA3049244A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
WO2019070435A1 (en) * 2017-10-05 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR SELECTIVE EXPANSION OF CELLS EXPRESSING A TCR WITH A CONSTANT MURINE REGION
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
CN109836490A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用
CN109837248A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
AU2019218785B2 (en) 2018-02-09 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
US12240870B2 (en) 2018-02-23 2025-03-04 Purdue Research Foundation Sequencing method for CAR T cell therapy
CA3097399A1 (en) 2018-04-19 2019-10-24 The Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
AU2019260656B2 (en) 2018-04-24 2025-08-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
WO2021011482A1 (en) * 2019-07-15 2021-01-21 Neogene Therapeutics B.V. Method to isolate tcr genes
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
US20230258635A1 (en) 2020-09-08 2023-08-17 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
WO2022104035A2 (en) 2020-11-13 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
JP2025501259A (ja) 2021-12-31 2025-01-17 アメリカ合衆国 がんに対する組合せ免疫療法としてのワクチン接種を伴うｔ細胞療法
CN117946247B (zh) * 2023-02-23 2024-08-09 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
BR112013003647A2 (pt) * 2010-07-28 2017-11-07 Immunocore Ltd receptores de células t.
CN110951690A (zh) * 2010-09-20 2020-04-03 生物技术细胞和基因治疗公司 抗原特异性t细胞受体和t细胞表位
WO2012054825A1 (en) * 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
PL2755997T3 (pl) 2011-09-15 2019-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7
US9413985B2 (en) * 2012-09-12 2016-08-09 Lattice Semiconductor Corporation Combining video and audio streams utilizing pixel repetition bandwidth
EP3636665B1 (en) * 2012-09-14 2022-06-29 The United States of America, as represented by The Secretary, Department of Health and Human Services T cell receptors recognizing mhc class ii-restricted mage-a3

Also Published As

Publication number Publication date
JP7270001B2 (ja) 2023-05-09
EP3636665A1 (en) 2020-04-15
AU2017219019B2 (en) 2019-05-09
JP2019088286A (ja) 2019-06-13
JP6923714B2 (ja) 2021-08-25
CA2884743A1 (en) 2014-03-20
PT2895509T (pt) 2020-03-13
JP2021191265A (ja) 2021-12-16
JP6728326B2 (ja) 2020-07-22
EP4159753A1 (en) 2023-04-05
KR102165350B1 (ko) 2020-10-14
HUE048014T2 (hu) 2020-05-28
US20200270329A1 (en) 2020-08-27
JP2015535816A (ja) 2015-12-17
AU2017219019A1 (en) 2017-09-14
EP2895509B1 (en) 2019-12-04
US10611815B2 (en) 2020-04-07
WO2014043441A1 (en) 2014-03-20
KR20220031941A (ko) 2022-03-14
JP2020178702A (ja) 2020-11-05
IL237560A0 (en) 2015-04-30
AU2013315391A1 (en) 2015-04-02
CY1122720T1 (el) 2021-03-12
PL2895509T3 (pl) 2020-07-27
JP6461796B2 (ja) 2019-01-30
KR20150052086A (ko) 2015-05-13
KR20210114563A (ko) 2021-09-23
CN113754755A (zh) 2021-12-07
AU2013315391B2 (en) 2017-06-08
AU2021203746B2 (en) 2024-05-02
CA2884743C (en) 2023-03-14
ES2774931T3 (es) 2020-07-23
LT2895509T (lt) 2020-03-25
AU2021203746A1 (en) 2021-07-01
US20150246959A1 (en) 2015-09-03
KR102303166B1 (ko) 2021-09-17
AU2019213329B2 (en) 2021-03-11
IL274003A (en) 2020-05-31
CN104968675A (zh) 2015-10-07
IL274003B (en) 2021-10-31
SMT202000103T1 (it) 2020-05-08
IL286786A (en) 2021-10-31
SI2895509T1 (sl) 2020-04-30
US9879065B2 (en) 2018-01-30
DK3636665T3 (da) 2022-10-03
MX2015003061A (es) 2015-11-06
CN104968675B (zh) 2021-09-24
EP3636665B1 (en) 2022-06-29
KR102480188B1 (ko) 2022-12-21
IL237560B (en) 2020-05-31
EP2895509A1 (en) 2015-07-22
ES2925307T3 (es) 2022-10-14
KR102370307B1 (ko) 2022-03-04
HRP20200325T1 (hr) 2020-06-12
DK2895509T3 (da) 2020-03-09
US12404317B2 (en) 2025-09-02
MX2019009641A (es) 2019-11-28
AU2019213329A1 (en) 2019-08-29
KR20200118248A (ko) 2020-10-14
IL286786B (en) 2022-09-01
US20180127479A1 (en) 2018-05-10
US20230089465A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
MX367279B (es) Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
MX2020003117A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
MX2017006865A (es) Receptores de células t de kras anti-mutado.
CO2021012587A2 (es) Receptores de células t mage a4
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
BR112014008849A2 (pt) receptores quiméricos de antígeno anti-cd22
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
AR088245A1 (es) Caracterizacion de la proteina y el gen cho-mif y uso de los mismos
CR20150477A (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
ECSP14024494A (es) Anticuerpos frente a los Ligandos del receptor B1 de bradicinina

Legal Events

Date Code Title Description
FG Grant or registration